Transdermal Rotigotine Improves Quality of Life in Patients with Parkinson's Disease: Presented at WPC, UCB Pharma Study
Doctor's Guide -- GLASGOW, Scotland -- October 5, 2010 -- Patients with Parkinson's disease (PD) who were treated with rotigotine for up to 12 weeks showed improvement in various activities of daily living, as well as in total health-related quality of life (HR-QOL), researchers said here at the 2nd World Parkinson Congress (WPC).